16Jan 2025
Aspirin Fails to Improve Disease-Free Survival in Colorectal Cancer

Aspirin Fails to Improve Disease-Free Survival in Colorectal Cancer

In a phase 3 trial of 1550 colorectal cancer patients, daily aspirin (200 mg) for 3 years post-adjuvant therapy did not significantly improve 5-year disease-free survival (77.0% vs. 74.8%, HR 0.91; p=0.38). Adverse events occurred in 49% of aspirin users and 51% of placebo users, with no treatment-related deaths. Aspirin was well tolerated but showed no added benefit for secondary prevention.

  • #gastroenterology

Like

Save

Share